focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
LO may have made a nice profit on the investment since December but like those of us who have been here sometime they bought large chunks of shares north of 50p. I maintain a spreadsheet of their purchases and disposals and they are just about even (the net cost of their current holding is pretty close to 25p).
Management bonuses are out of order.
Payment to Derek Martin was probably necessary. It makes it look as if FUM let him go but I think it was the other way round. I think he lost patience.
The problem for MFTB is that if they need to do further work, they will need to raise funds. To some of doomsters here, the cash position in IMM may be dwindling but there is no immediate or short-term need to raise funds.
For the bid to succeed, BVS would have to offer a cash element. I am surprised that they divulged so much detail about the proposed offer, They could have said negotiations took place but have now finished without going into details. This must be a carrot to GRFD's institutional shareholders to think again but GFRD without LInden Homes is not very exciting proposition.
Genuinely sorry to read all this. After Badile in 2017 Idecided to bail out. JP's flashy cufflinks, presentation style, and the cornerstone investor were negatives I also wasn't happy with the unexplained departure of the then finance officer in early 2017.
There have been two RNS since close last night. Blackrock have, I suspect, sold their entire 5.33% stake. The new shareholder (unkown to me) has a 12% stake. Another institution must have sold so another RNS awaited.
Looking at Level 2, trades look to be duplicated but HL is recording four large trades which represent 30% of market cap, possibly a switch between institutions.
Over the past couple of years AIM stocks have had a bad run with the FDA (IMM, MTFB, STX). For STX and IMM it was efficacy, for MTFB safety. They are all still trying to get approval. Acknowledge that FUM is not a pure pharma product. I am sure it is safe, and I can confirm from direct experience that Cialiis and Levitra have unpleasant side effects. It would also be logical that direct application will act more quickly rather than via the blood stream. Statistically significant efficacy over the placebo will be the key.
@Maestro
You wrote yesterday "The testing is going great with no adverse side effects". How do you know that the product is meeting "to pardon the expression" the end points in the Phase III trial? Do we know how many people have now signed up?
Charting is useful for tracking the history of the SP, identifying past support and resistance levels, but is of little use on AIM where the price is mostly event driven allied with an absence of constantly loyal institutional support.
There was clearly a ramping exercise earlier in the month which took the sp to £1. Good to get additional funds at this price. I hope this is used solely in Guyana. Reduces the risk. News from JOG yesterday was a reminder of the risks in oil exporation.